Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from Financing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares IssuedShort-Term Debt repayments
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Palisade Bio (PALI) Change in Acquisitions & Divestments (2014 - 2018)

Palisade Bio (PALI) reported Change in Acquisitions & Divestments of $5.0 million for Q1 2018, down 33.49% on a QoQ basis from $7.5 million in Q1 2016.

Palisade Bio (PALI) has 4 years of Change in Acquisitions & Divestments data on file, last reported at $5.0 million in Q1 2018.

  • Quarterly Change in Acquisitions & Divestments changed N/A year-over-year to $5.0 million in Q1 2018, while the trailing twelve-month figure through Dec 2018 was $5.0 million (changed N/A YoY) and the FY2018 annual result came in at $5.0 million, changed 0.0% from the prior year.
  • Change in Acquisitions & Divestments declined to $5.0 million in Q1 2018 per PALI's latest filing, from $7.5 million in the prior quarter.
  • Across five years, Change in Acquisitions & Divestments topped out at $15.0 million in Q1 2015 and bottomed at $5.0 million in Q1 2018.
  • The 4-year median for Change in Acquisitions & Divestments is $8.8 million (2014), against an average of $9.4 million.
  • Peak annual rise in Change in Acquisitions & Divestments reached 49.91% in 2016, while the deepest fall reached 49.91% in 2016.
  • Tracing PALI's Change in Acquisitions & Divestments over 4 years: stood at $10.0 million in 2014, then jumped by 50.07% to $15.0 million in 2015, then slumped by 49.91% to $7.5 million in 2016, then sank by 33.49% to $5.0 million in 2018.
  • Per Business Quant, the three latest PALI Change in Acquisitions & Divestments figures stand at $5.0 million (Q1 2018), $7.5 million (Q1 2016), and $15.0 million (Q1 2015).

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Quantum Biopharma 961,148.99 Bn 961,148.98 Bn -
2 Alterity Therapeutics 744,933.29 Bn 744,933.26 Bn -
3 Legend Biotech 2,540.00 Bn 2,539.71 Bn 242.10 Mn
4 Nanobiotix 2,199.85 Bn 2,199.78 Bn -
5 Akari Therapeutics 1,635.88 Bn 1,635.88 Bn -
6 Vertex Pharmaceuticals 111.32 Bn 104.07 Bn 2.59 Bn
7 Evaxion A 62.56 Bn 62.54 Bn -
8 Regeneron Pharmaceuticals 62.55 Bn 53.79 Bn 3.31 Bn
9 Alnylam Pharmaceuticals 39.57 Bn 36.56 Bn 959.66 Mn
10 Palisade Bio 439.25 Mn 309.68 Mn -

Historic Data

Download Data 🔒
DateValue
Mar 31, 2018 5.00 Mn
Mar 31, 2018 5.00 Mn
Mar 31, 2016 7.52 Mn
Mar 31, 2016 7.52 Mn
Mar 31, 2015 15.01 Mn
Mar 31, 2015 15.01 Mn
Sep 30, 2014 10.00 Mn
Sep 30, 2014 10.00 Mn